# Academíc Sciences

#### International Journal of Pharmacy and Pharmaceutical Sciences

#### ISSN- 0975-1491

*t - 270* Vol 4, Suppl 1, 2012

## **Research Article**

# GROWTH CHARACTERIZATION OF CALCIUM OXALATE MONOHYDRATE CRYSTALS INFLUENCED BY COSTUS IGNEUS AQUEOUS STEM EXTRACT

#### K. MANJULA<sup>a</sup>, K. PAZHANICHAMY<sup>a</sup>, S. KUMARAN<sup>a</sup><sup>\*</sup>, T. EEVERA<sup>b</sup>, C. DALE KEEFE<sup>c</sup> AND K. RAJENDRAN<sup>a</sup>

<sup>a</sup>Department of Biotechnology, Periyar Maniammai University, Thanjavur, Tamilnadu, India, <sup>b</sup>Dryland Agricultural Research Station, Tamil Nadu Agriculture University, Chettinad, Tamil Nadu, India, <sup>c</sup>Department of Chemistry, Cape Breton University, Sydney, Nova Scotia, B1P 6L2, Canada. Email: nkraj64@yahoo.co.uk

#### Received: 23 Sep 2011, Revised and Accepted: 23 Nov 2011

## ABSTRACT

Calcium oxalate monohydrate (COM) and calcium oxalate dihydrate (COD) are frequently found in urinary calculi (stones). COM crystals were grown using both gel and liquid growth methods, and the inhibitory effect of aqueous *Costus igneus* stem extract on the growth of COM crystals was studied. The results indicate that with an increase in the concentration of aqueous *C igneus* extract, the mass of the formed crystals was gradually reduced from 2.16 g to 0.08 g and from 2.89 g to 0.035 g for the gel and liquid methods, respectively. The crystals were characterized by Fourier transform infrared spectroscopy (FTIR) to confirm the functional groups and powder Xray diffraction (XRD) analyses to confirm the phases of the COM and COD crystals. Scanning electron microscopy (SEM) confirmed that the morphology of the crystals changed from hexagonal to bipyramidal, which is characteristic of a change from COM to COD. The average size of the crystals from the gel method was reduced from 1874.1 x 857.8 µm to 1075.5 x 990.5 µm from 0.524 µm to 0.291 µm using the liquid method. Lupeol and the Stigmasterol are the active compound were identified and isolated by High performance thin layer chromatography (HPTLC) techniques. This study confirms that the use of aqueous *C. igneus* extracts can promote the formation of COD crystals and reduce the nucleation rate of COM rrystals, a major component of oxalate urinary stones.

Keywords: Nucleation, Characterization, Crystal Morphology, X-Ray Diffraction, Calcium Oxalate Monohydrate, Costus igneus

#### INTRODUCTION

Many people suffer from problems resulting from urinary stones. Calcium-containing stones are the most common variety of urinary stone, and they comprise about 75% of all urinary calculi, which are found in the form of pure calcium oxalate (50%), calcium phosphate (5%) or a mixture of both (45%) <sup>1-5</sup>. Calcium oxalate (CaOxa) is a major component of urinary stones that is generally found in two different varieties, calcium oxalate monohydrate (COM), or the store of the st Whewellite, and calcium oxalate dihydrate (COD), or Weddellite. It is difficult to form urinary stones from COD because COD crystals are unstable and are easily excreted in the urine of both humans and animals<sup>6-11</sup>. The formation of COD crystals actually protects against stone disease because of their reduced capacity to form stable aggregates or strong adhesion contacts to renal epithelial cells<sup>12</sup> due to the single micron-sized crystals. Urinary stones are characterized by high recurrence rates and would therefore benefit from a preventive treatment using medicinal plants<sup>13-15</sup>. *Costus igneus*, also known as Fiery Costus, Spiral Flag or Insulin Plant, belongs to the Costaceae family. It contains a range of phytochemicals<sup>16</sup>, such as flavonoids, alkaloids and terpenoids, and is traditionally used in India to control diabetes17. Administration of the aqueous extract of C. spiralis to rats with experimentally induced urolithiasis has been found to reduce the growth of urinary stones18. Additionally, the blood glucose levels of alloxaninduced diabetic rats were controlled after the administration of ethanolic extracts of C. igneus leaves19 However, it has been cautioned that the constant use of *C. pictus* increases the LDL to HDL cholesterol ratio<sup>17</sup> due to higher levels (24.51% in leaves, 28.30% in the stem and 25.26% in the rhizome) of hexadecanoic acid found in diethyl ether extractions<sup>20</sup>. In the present study, the effects of aqueous *C. igneus* stem extracts on the nucleation and growth of CaOxa crystals, using both gel and liquid growth methods, are reported for the first time. Lupeol and the Stigmasterol were identified and isolated by HPTLC techniques. This study incorporates a multidisciplinary approach for the characterization of COM crystals grown *in vitro* to facilitate the development of prevention and dissolution strategies aimed at managing urinary stone growth.

# MATERIALS AND METHODS

#### Materials and instruments

Anhydrous ethanol, calcium chloride, sodium oxalate, magnesium acetate, oxalic acid and sodium metasilicate were purchased from Sigma-Aldrich (New Delhi, India) and were labeled analytical grade. All reagents and double distilled water were used without further purification. Fourier Transform Infrared (FTIR) spectra were recorded with a nominal resolution of 4 cm-1 and a wave number range from 400 to 4000 cm-1 using the KBr pellet technique. Powder X-Ray Diffraction (XRD) was performed with a PW1710 diffractometer using CuK $\alpha$  radiation. Scanning Electron Microscopy (SEM) with an accelerating voltage of 20 kV was utilized to analyze our products.

#### Collection and extraction of plant materials

The medicinal plant *C. igneus* was collected from the herbarium of the Periyar Maniammai University, Vallam, Thanjavur and identified at the Rapinat Herbarium, St. Joseph College, Tiruchirapalli, Tamil Nadu, India. The *C. igneus* aqueous extract (A.E) was prepared by boiling 25 g of *C. igneus* stems in 100 mL distilled water for 30 minutes and then filtering through Whatman filter paper twice<sup>3</sup>. The filtrate was condensed using a rotary evaporator and the obtained residue (1.4 g) was used to prepare the series of aqueous supernatant concentrations for *in vitro* studies shown in Table 1.

#### Growth and characterization of COM crystals with gel methods

Glass test tubes were used as a crystallization apparatus, and the single diffusion reaction technique was employed. A solution of Na2SiO3•9H2O (density of 1.04 g/cm3 at pH 9.4) was mixed with 1M (COOH)2•2H2O so that the pH of the mixture was maintained at 5, and it was left undisturbed for 2-3 days. After gelation occurred, a supernatant solution of 1 M CaCl2 and 1 M MgCH3COO2•4H2O was gently poured onto the set gel. After adding the supernatant solution, the test tubes were capped airtight. All experiments were conducted at a temperature of 37  $\pm$  2°C.

#### Int J Pharm Pharm Sci, Vol 4, Suppl 1,261-270

# The nomenclature of different additive solutions on the growth of COM crystals with the gel method

An attempt was made to investigate the putative activity of the plant extracts as inhibitors of COM crystal formation in the gel method. The supernatant solutions shown in Table 1 were added to the set gels and the results were noted. The experiments were repeated four times. To study the effects of the aqueous extract of *C. igneus* on the growth of COM crystals, five different concentrations of the plant extracts (see Table 1) were added to equal amounts of the supernatant solution, and the average weights of the grown crystals were measured.

Table 1: Supernatant solutions added to the set gels for COM crystals

Supernatant Solutions (Groups and Treatments)	Compositions
I (CONTROL)	<u>10 mL of 1M CaCl<sub>2</sub> + 10 mL of 1M (CH<sub>3</sub>COO<sub>2</sub>)Mg.4H<sub>2</sub>O</u>
II (DIST.H <sub>2</sub> O)	<u>5 mL of 1M CaCl<sub>2</sub> + 5 mL of 1M (CH<sub>3</sub>COO<sub>2</sub>)Mg.4H<sub>2</sub>O + 10 mL of distilled water</u>
<u>III (0.15% A.E)</u>	5 mL of 1M CaCl <sub>2</sub> + 5 mL of 1M (CH <sub>3</sub> COO <sub>2</sub> )Mg.4H <sub>2</sub> O + 10 mL of 0.15% aqueous extract of stem of
	<u>Costus igneus</u>
<u>IV (0.25% A.E)</u>	5 mL of 1M CaCl <sub>2</sub> + 5 mL of 1M (CH <sub>3</sub> COO <sub>2</sub> )Mg.4H <sub>2</sub> O + 10 mL of 0.25% aqueous extract of stem of
	<u>Costus igneus</u>
<u>V (0.50% A.E)</u>	$5 \text{ mL of } 1M \text{ CaCl}_2 \pm 5 \text{ mL of } 1M (CH_3COO_2)Mg.4H_2O \pm 10 \text{ mL of } 0.50\% \text{ aqueous extract of stem of}$
	<u>Costus igneus</u>
<u>VI (0.75% A.E)</u>	5 mL of 1M CaCl <sub>2</sub> + 5 mL of 1M (CH <sub>3</sub> COO <sub>2</sub> )Mg.4H <sub>2</sub> O + 10 mL of 0.75% aqueous extract of stem of
	<u>Costus igneus</u>
<u>VII (1.00% A.E)</u>	5 mL of 1M CaCl <sub>2</sub> + 5 mL of 1M (CH <sub>3</sub> COO <sub>2</sub> )Mg.4H <sub>2</sub> O + 10 mL of 1.0% aqueous extract of stem of
	Costus igneus

## Growth and characterization of COM crystals with liquid methods

In the liquid method, 15 mL of 5 mmol/L CaCl2 solution was added to 30 mL of 0.15, 0.25, 0.50, 0.75 and 1.00% (w/v) aqueous *C. igneus* extract and was thoroughly mixed. The solution was combined with 15 mL of 5 mmol/L Na2C2O4 solution and was thoroughly mixed again. A corresponding control experiment was carried out by reacting CaCl2 with Na2C2O4 under the same conditions, without the addition of any additives. The mixtures were covered with Parafilm and stored at 10°C for 3 days. The products were then carefully extracted from the aqueous solution, washed three times with ethanol and double distilled water, and dried for further characterization using FTIR, powder XRD and SEM technique<sup>40</sup>.

#### Isolation and Identification of active compounds

#### Sample preparation

All the chemicals, including solvents, were of analytical grade from E. Merck, India. The HPTLC plates Si  $60F_{254}(20\,\text{cmX10cm})$  were purchased from E. Merck (India). Standards of Lupeol(97% purity), Stigmasterol (99% purity) were purchased from Sigma (New Delhi, India). 100mg/ml of ethanolic extracts of stem of *Costus igneus* was taken for analysis. The extracts were filtered and vacuum dried at 45°C.The dried extracts were separately redissolved in 1ml of ethanol and sample of varying concentration (1-3  $\mu$ ) for Lupeol and (5-30  $\mu$ ])

for Stigmasterol -were spotted for quantification. 1mg of standard 1 (Lupeol) and Standard 2 (Stigmasterol) were prepared in 1ml of chloroform, and different amounts of (5000-10000 ng) Lupeol and (1000-6000 ng) Stigmasterol were loaded onto a TLC plate to get the calibration curve<sup>23</sup>.

## Thin layer chromatography

A Camag HPTLC systemsA Camag HPTLC system equipped with an automatic TLC sampler ATS4, TLC scanner 3 and integrated software Win CATS version 3, was used for the analysis. Samples were washed on a pre-coated silica gel HPTLC plates Si 60F<sub>254</sub>(20cm x 10cm) plate of 200µm-layer thickness, for quantification of Lupeol and stigmasterol in stem of *Costus igneus*. The samples and standards were applied on the plate as 8mm wide bands with a constant application rate of 150Nl s<sup>-1</sup>, with an automatic TLC sampler (ATS4) under a flow of N<sub>2</sub> gas, 15mm from the bottom, 15mm from the side, and the space between two spots was 6mm in the plate.

Detection and Estimation of Lupeol and Stigmasterol

The linear ascending development was carried out in a Camag twin through chamber (20cm x 10cm), which was pre-saturated with a 25ml mobile phase, with n-Hexane : Ethyl acetate (80:20v/v) for lupeol, Toluene: Acetone: Acetic acid (8.9: 0.9: 0.2: v/v/v) for stigmasterol for –30 minutes, at room temperature ( $25^{\circ}C\pm^{2}c$ ) and  $50\pm5\%$  relative humidity. The length of the chromatogram run was up to 90 mm. Subsequent to the development; the TLC plate was dried in a current of air, with the help of air dryer, in a wooden chamber with adequate ventilation. The dried plate was dipped into freshly prepared Anisaldehyde sulphuric acid Reagents and subsequently in Libermann Burchard reagent. Quantitative estimation of the plate was performed in the absorption-reflection mode at 538nm, using a slit width 6.00 x 0.45 mm, with data resolution 100 $\mu$ m/step and scanning speed 20mm/sec. The source of radiation utilized was a performed by the external standard method, using pure standards. Each was carried out in triplicate.

#### **Calibration Curve and Linearity**

The calibration were performed by analysis of working standard solutions of Lupeol (5000 to 10000ng for *Costus igneus*), Stigmasterol (1000 to 6000ng for *Costus igneus*) were spotted on precoated TLC plate, using semiautomatic spotter under nitrogen stream. The TLC plates were developed, dried by hot air and photometrically analyzed as described earlier. The calibration curves were prepared by plotting peak area verus concentration (ng/spot) corresponding to each spot.

#### Statistical Analysis

The masses of the crystals are presented as the mean  $\pm$  SD for the control and treatment samples. One-way analysis of variance (ANOVA), followed by Tukey's test for multiple comparisons, was made between the groups shown in Table 2. Values of p <0.05 were considered significant.

#### RESULTS AND DISCUSSION

#### Effect of C. igneus extract on COM crystals

The effect of the aqueous *C. igneus* stem extract on the nucleation and crystallization characteristics of COM was determined by measuring the mass of the formed crystals. We found that the aqueous extract favored the formation of the dihydrate (metastable) form of calcium oxalate crystals in both the gel and liquid methods. In both the gel and liquid methods, the control solutions led to the maximum nucleation of crystal growth within 24 h of adding the supernatant solutions (Fig. 1).

## Int J Pharm Pharm Sci, Vol 4, Suppl 1,261-270

In the presence of the aqueous *C. igneus* stem extract, nucleation was delayed and reduced crystal masses were observed 96 h following addition of the supernatant solutions. As the concentration of aqueous *C. igneus* extract increased from 0.15% to 1.00% (w/v), the average weights of the formed crystals gradually decreased from 2.16 g to 0.08 g and from 2.89 g to 0.035 g for the gel and liquid methods, respectively. ANOVA was performed for the crystal masses, and a p <0.05 suggested that the correlation was significant as shown in Table 2. The crystal masses from Group III to VII, treated with various concentrations of aqueous *C. igneus* extract ranging from 0.15% to 1%, were significantly different at p <0.05 when compared to Group I, the untreated control. However, Group I, which was treated with distilled water, was not significantly different at p <0.05 compared to Group I.

This result indicates that distilled water did not show any inhibitory activity with regard to crystal growth, whereas the aqueous extract of *C. igneus* possessed inhibitory activity due to the presence of bioorganic molecules<sup>16</sup>. Group VI and VII, treated with 0.75% and 1% aqueous extracts, respectively, were not significantly different. In general, an increase in aqueous extract concentrations resulted in a decrease in the crystal mass due to a reduction in the sizes of the crystal during treatments. Morphology of the harvested crystals changed from hexagonal (COM) to tetragonal (COD) as shown in (Fig. 2). In the present study, COM crystal growth was reduced, and the morphology of the crystals was altered due to the inhibitory effect of aqueous *C. igneus* extracts under *in vitro* conditions by the gel and liquid methods, as has previously been reported<sup>1-3,11,26</sup>.

Table 2: ANOVA statistical analysis for harvested crystals

Groups	Treatments	<u>Mean (g)±S.D Gel Liquid</u>	
Ī	<u>Control</u>	$2.16 \pm 0.05$ $2.89 \pm 0.04$	
<u>11</u>	Distilled water	$2.07\pm0.09^{a\cdot ns}$ 2.8±0.08 <sup>a-ns</sup>	
<u>III</u>	0.15% extract	$1.6 \pm 0.08^{a,b}$ $1.07 \pm 0.01^{a,b}$	
IV	0.25% extract	$0.6 \pm 0.08^{a,b,c} 0.42 \pm 0.05^{a,b,c}$	
V	0.50% extract	$0.31\pm0.01$ a,b,c,d $0.19\pm0.02$ a,b,c,d	
VI	0.75% extract	$0.11 \pm 0.008^{a,b,c,d} \\ 0.07 \pm 0.008^{a,b,c,d}$	
VII	<u>1.00% extract</u>	$0.08 \pm 0.006^{a,b,c,d,e,f-ns} 0.035 \pm 0.006^{a,b,c,d,e,f-ns}$	

Values represent mean (g) ± S.D (n=4)

Comparisons between means are as follows. (a) I vs II-VII. (b) II vs III-VII. (c) III vs IV-VII. (d) IV vs V-VII. (e) V vs VI-VII. (f) VI vs VII.

a-ns, f-ns were not significantly different, Statistical significance were considered to be ap<0.05, bp<0.05, bp<0.05, dp<0.05, bp<0.05, bp<0.05, dp<0.05, bp<0.05, dp<0.05, d



## Int J Pharm Pharm Sci, Vol 4, Suppl 1,261-270

Fig. 1: Effect of *Costus igneus* extract on COM crystals (a) without any additive after 24hrs, 48hrs and 7<sup>th</sup> days (b) with the *Costus igneus* extract after 24hrs, 48hrs and 7<sup>th</sup> days



Fig. 2: Morphology of the harvested COM crystals (a) without any additives, (b) with the 0.15% (w/v) Costus igneus extract obtained using the gel methods

#### Characterization of harvested crystals

The changes in the morphology of CaOxa crystals obtained from SEM studies in the absence and presence of the *C. igneus* stem extract using both the gel and liquid methods (Fig.3). In the gel method, the CaOxa crystals that were formed in the absence of any additive were elongated hexagonal (Fig. 3(a)) with an average size of 1874.1 x 857.8  $\mu$ m. In the presence of the *C. igneus* stem extract, the CaOxa crystals were elongated tetragonal bipyramidal (Fig. 3(b)) with an average size of 1075.5 x 990.5  $\mu$ m. In the liquid method (Fig. 3(c)), the CaOxa

crystals formed in the absence of any additive were elongated hexagonal with an average size of 0.524  $\mu$ m and 0.563  $\mu$ m. In the presence of the *C. igneus* stem extract, the Ca0xa crystals were elongated tetragonal bipyramidal with an average size of 0.291 x 0.239  $\mu$ m and 0.295 x 0.272  $\mu$ m (Fig. 3(d)).

The COM crystals grown displayed many different morphologies, but the most prominent faces were (100), (001), (101), (021). COD crystals usually appeared as bipyramids with (101) being the dominant face as was previously reported<sup>21,22</sup>.



Int J Pharm Pharm Sci, Vol 4, Suppl 1,261-270



Fig. 3: SEM images of CaOxa crystals (a) and (c) without any additives, (b) and (d) with the 0.15% (w/v) Costus igneus extract obtained using the gel and liquid methods

The FTIR spectra of CaOxa crystals obtained in the presence and absence of the *C. igneus* extract, using both the gel and liquid methods (Fig. 4 and 5). In Fig. 4(a), the peaks at 1642 and 1330 cm-1 are the main antisymmetric carbonyl stretching bands, and the band at 1031 cm-1 shows C-0 stretching. The band at 886 cm-1 is due to C-C stretching, which reveals the presence of two carboxylate anions. This confirms the existence of the oxalate group in COM crystals. In Fig. 4(b), shifts from 1642 cm-1 for COM to 1635 cm-1 for COD as well as from 1330 cm-1 for COM to 1386 cm-1 for COD were observed, and the band at 1007 cm-1 is due to C-O stretching. The band at 877 cm-1 demonstrates a C-C stretch, which reveals the existence of an oxalate group in the COD crystals. In Fig. 5(a), the peaks at 1636 cm-1 and 1326 cm-1 tore the main antisymmetric carbonyl stretching bands, and the band at 1024 cm-1 is due to the C-O stretching. This result indicates the presence of a carboxylate anion in COM crystals. In Fig. 5(b), shifts from 1636 cm-1 for COM to 1639 cm-1 for COD as well as from 1326 cm-1 for COM to 1639 cm-1 for COM to 1639 cm-1 for COM at 1024 cm-1 is due to the C-O stretching. This result indicates the presence of a carboxylate anion in COM crystals. In Fig. 5(b), shifts from 1636 cm-1 for COM to 1639 cm-1 for COD as well as from 1326 cm-1 for COM to 1639 cm-1 for COD as well as 1024 cm-1 is due to the C-O stretching. This result indicates the presence of a carboxylate anion in COM crystals. In Fig. 5(b), shifts from 1636 cm-1 for COM to 1639 cm-1 for COD as well as 1600 cm-1 for COD at 1636 cm-1 for COD at the band at 1024 cm-1 is due to the C-O stretching. This result indicates the presence of a carboxylate anion in COM crystals. In Fig. 5(b), shifts from 1636 cm-1 for COM to 1639 cm-1 for COD as well as 1600 cm-1 for COD at the code cm-1 for COD at the code cm-1 for COD at the code cm-1 for COD at the cm-1 for COD at the code cm-1 for COD at the cm-

addition, two bands located at 925 cm-1 and 654 cm-1 were also assigned to COD. Figs. 4(c) and 5(c) display the FTIR spectra of the raw stem powder of *C. igneus*, which is rich in protein, iron, antioxidant components and phytochemicals (i.e., flavonoids, alkaloids, terpenoids, steroids, saponins and phenolics). Figs. 4(d) and 5(d) show the FTIR spectra of the aqueous extract powder of *C. igneus* containing watersoluble phytochemicals, which were separated according to the polarity of the solvent<sup>16</sup>. There were no impurities found in the *C. igneus* treated COD crystals (Figs. 2(b) and 3(b)).

The peaks at 1618 cm-1 and 1318 cm-1 are the main antisymmetric carbonyl stretching bands specific to the oxalate family and the metal carboxylate stretch for COM, respectively. The peaks shifted from 1618 cm-1 to 1652 cm-1 or 1647 cm-1 and from 1318 cm-1 to 1328 cm-1 or 1327 cm-1 for COD, as previously reported<sup>7,10,11,21</sup>. The shifting further supports the hypothesis that *C. igneus* stem extracts favor the nucleation and or transformation of COM into COD.

Int J Pharm Pharm Sci, Vol 4, Suppl 1,261-270



Fig. 4: FTIR spectra of CaOxa crystals obtained from the gel method (a) without any additives, (b) with 0.15% (w/v) C. igneus extract, (c) raw stem powder of C. igneus and (d) aqueous extract powder of C. igneus stem

Int J Pharm Pharm Sci, Vol 4, Suppl 1,261-270



Fig. 5: FTIR spectra of CaOxa crystals obtained from the liquid method (a) without any additives, (b) with 0.15% (w/v) C. igneus extract, (c) raw stem powder of C. igneus and (d) aqueous extract powder of C. igneus stem

Fig. 6 shows the XRD patterns of CaOxa crystals obtained in the presence and absence of the *C. igneus* extract using both the gel (Fig. 6(a) and 6(b)) and liquid methods (Fig. 6(c) and 6(d)). The diffraction peaks obtained in both methods correlate well to the (hkl) indices of the COM phase (JCPDS card number 20-231) and the COD phase (JCPDS card number 17-541). As reported previously<sup>3,11</sup>, the diffraction peaks 14.95, 24.39, 30.12 and 33.13 for COM as well as 14.26, 20.01, 24.15, 32.17, 37.21 and 40.00 for COD were assigned. It is inferred from the above results that the *C. igneus* stem extract affected the nucleation and growth of COD crystals.

## Quantitative determination of Lupeol and Stigmasterol in extracts of *Costus igneus* by HPTLC technique

HPTLC fingerprint patterns have been therefore evolved for extracts of *Costus igneus*. Lupeol standard was quantitated accurately using silica gel  $F_{254}$  HPTLC pre-coated plates with the mobile phase for n-Hexane : Ethyl acetate (80:20v/v),the Rf value for Lupeol was about 0.55. The chromatographs of Lupeol and ethanol extract of *costus* 

igneus are shown in (Fig. 7(a)). The Rf value of Lupeol was matched with the Rf value of *Costus igneus* extract was about 0.55. Stigmasterol standard was quantitated accurately using silica gel  $F_{254}$ HPTLC pre-coated plates with the mobile phase Toluene: Acetore Acetic acid (8.9: 0.9: 0.2 v/v/v), the Rf value was about 0.58. The chromatographs of stigmasterol and ethanol acetate of *Costus igneus* are shown in (Fig. 7(b)). The Rf value of stigmasterol was matched with the Rf value of extract was about 0.58. The amount of Lupeol (0.473 mg/100 mg) and Stigmasterol (1.913 mg/100 mg) in stem of *Costus igneus*.

A pentacyclic triterpenoid compound Lupeol and a steroid compound Stigmasterol were identified and isolated by HPTLC techniques for the first time. Previous study has reported that Lupeol, a triterpene compound has been isolated from *Crataeva nurvala* showed antioxaluric and anticalciuric effects in rats against hydroxyprolineinduced hyperoxaluria<sup>24</sup>. The earlier investigators isolated lupeol from the methanol extract of stem bark of *Grewia titiaefolia* and evaluated the cytotoxic properties on *in vitro* cell lines<sup>25</sup>.



Fig. 6: XRD patterns of CaOxa crystals (a) and (c) without any additives. (b) and (d) with the 0.15% (w/v) C. igneus extract obtained using the gel and liquid methods. \* denotes COD crystals



Fig. 7: (a) HPTLC chromatogram of Lupeol in C. igneus extract (b) HPTLC chromatogram of Stigmasterol in C. igneus extract

#### Int J Pharm Pharm Sci, Vol 4, Suppl 1,261-270

#### Calibration curve and Linearity

The calibration curve was prepared by plotting peak area versus concentration (ng/spot) corresponding to each spot. The regression equation and correlation curves for Lupeol in Costus igneu were, regression via height y=149.076+32.745X and r=0.99794 sdv=0.72, regression via area y=213.109+1731.406X and r=0.99914 sdv=0.72. Stigmasterol in *Costus igneus* were, regression via height y=116.129+0.052X and r=0.99956 sdv=1.78, regression via area y=1732.776+2.151X and r=0.99999 sdv=0.08.

CONCLUSION

COM crystals were grown using both gel and liquid growth methods and were characterized by SEM, FTIR and Powder XRD techniques. The COM crystal growth was reduced, and the morphology of the crystals changed from a hexagonal (COM) to a bipyramidal (COD) form due to the inhibitory action of the aqueous extracts of C. igneus under in vitro conditions. FTIR and Powder XRD techniques confirmed the functional groups and crystalline phases of the  $\dot{COM}$  and COD crystals. SEM studies confirmed the morphology of the changed crystals. It also confirmed that the average size of the crystals was reduced from  $1874.1 \times 857.8 \ \mu m$  to  $1075.5 \times 990.5 \ \mu m$  and from  $0.524 \ \mu m$  to  $0.291\ \mu\text{m}$  for the gel and liquid methods, respectively. One-way ANOVA performed with treated and untreated crystal growth data obtained from both the gel and liquid methods showed significant differences (p <0.05). This inhibitory effect may be due to the presence of a terpenoid compound lupeol and a steroid compound stigmasterol from the stem of Costus igneus were identified by HPTLC techniques. This study confirmed that aqueous C. igneus extracts promote the formation of COD crystals and may possibly treat urinary stones by inhibiting the formation of COM crystals, which are a major component of urinary stones. This study was focused on finding a new alternative medicine for the treatment of calcium oxalate urinary stone.

## ACKNOWLEDGEMENT

KS acknowledges DBT, New Delhi (BT/PR10018/NNT/28/95/2007) for providing financial support. KM acknowledges DBT for a Junior Research Fellowship and Dr. S. John Britto for identifying the plants. CDK thanks the Canada Research Chairs program, Cape Breton University and the Natural Sciences and Engineering Research Council Canada (NSERC) for their financial support of this work. KR thanks Cape Breton University, Canada for a visiting fellowship during this work

#### REFERENCES

- 1 Beghalia M, Ghalem S, Allali H, Belouatek A, Marouf Ant Effect of herbal extracts of *Tetraclinis articulate* and *Chamaerops humilis* on Calcium oxalate crystals in vitro. Gomal J. Med. Sci. 2007; 5(2): 55-58
- Beghalia M, Ghalem S, Allali H, Belouatek A, Marouf A.: Inhibition 2. of calcium oxalate monohydrate crystal growth using Algerian medicinal plants. J. Medicinal Plants Research. 2008; 2(3): 066-070
- 3. Joshi VS, Parekh BB, Joshi MJ, Vaidya AB .: Herbal extract of Tribulus terrestris and Bergenia ligulat inhibit growth of calcium oxalate monohydrate crystals in vitro, J. Cryst. Growth. 2005; 275: 1403-1408.
- 4 El-Shall H. Jeon IH. Abdel-Aal EA. Khan S. Gower L. Rabinovich Y. A study of primary nucleation of calcium oxalate monohydrate: II. Effect of urinary species. Cryst. Res. Technol. 2004; 39(7): 577-585
- Ramegowda Basavaraj D, Shakhar Biyani C, Browning AJ, Cartledge J, $_{\pm}$  The role of Urinary Kidney Stone inhibitors and 5 promoters in the pathogenesis of calcium containing renal stones.
- Eur. <u>Asso. Urol. 2007; 5: 26-136.</u> Bouropoulos C, Vagenas N, Klepetsanis P, Stavropoulos N, 6. Bouropoulos N.: Growth of calcium oxalate monohydrate on uric

acid crystals at sustained supersaturation. Cryst. Res. Technol. 2004; 39(8): 699-704.

- Anjian X, Yuhua S, Dong M, Fangzhi H, Lingguang Q, Shikuo L, Chen  $L_{\rm c}$  Growth of calcium oxalate crystals induced by complex films containing biomolecules. Cryst. Res. Technol. 2007; 42(7): 667-672.
- Monje PV, Baran EJ.: Characterization of calcium oxalate generated as biominerals in cacti. Plant Physiol. 2002; 128: 707-713.
- g spectroscopic analysis. Ind. J. Pure and Appl. phys. 2010; 48(8): 36-38.
- [10] Yongtai Z, Jiansheng T, Nianping F, Xiangdong H & Crystal 10. growth of calcium oxalate induced by the extracts of Semen plantaginis and Folium pyrrosiae. Cryst. Res. Technol. 2008; 43: . 931-934.
- 11. Sheng X, Ward MD, Wesson  $JA_{\pm}$  Crystal surface adhesion explains the pathological activity of calcium oxalate hydrates in kidney stone formation. J. Am. Soc. Nephrol. 2005; 16: 1904-1908. Wesson JA, Ward MD. Pathological Biomineralization of kidney
- 12. stones. Elements. 2007; 3: 415-421.
- Aggarwal S. Tandon CD. Forouzandeh M. Singla SK. Kiran R. Jethi 13 RK + Role of biomolecules from human renal stone matrix on COM crystal growth. Mol. Cell. Biochem. 2000; 210: 109-119. Fouad A, Yamina S, Mostapha M, Mohammed A, Brahim  $\overline{H}_{s}$  Effect
- 14. of aqueous extract from Herniaria hirsute L. on experimentally
- nephrolithiasic rats. J. Ethnopharmacol. 2004; 95(1): 87-93. Bensatal A, Ouahrani MR.: Inhibition of crystallization of calcium 15. oxalate by the extraction of Tamarix gallica. Urol. Res. 2008; 36(6): 283-287.
- Devi VD, Urooj A.+ Nutrient profile and antioxidant components of 16. Costus speciosus Sm. and Costus igneus Nak. Indian J. Nat. Prod. Resour. 2010; 1(1): 116-118.
- 17. Devi VD, Urooj A $\div$  Hypoglycemic potential of Morus indica L and Costus igneus Nak - A preliminary study. Indian J. Exp. Biol. 2008; 46(8): 614-616.
- Araiyo viel T, Diogo Domingos C, Paula da Silva Monteiro A, 18. Teresa Riggio Lima- Landman M, Jose lopa A, Souccar C.+ Evaluation of the antiurolithiatic activity of the extract of Costus spiralis Roscoe in rats. J. Ethnopharmacol. 1999; 66: 193-198
- 19. Bhat V, Naveen A, Akshay K, Sikarwar Mukesh S, Patil MB.:-Antidiabetic activity of insulin plant (Costus igneus) leaf extract in diabetic rats, J. Pharmacy Res. 2010; 3 (3): 608-611.
- 20 Jose B, Reddy LJ - Analysis of the essential oils of the stems, leaves and rhizomes of the medicinal plant Costus pictus from Southern India. Int. J. Pharmacy Pharma. Sci. 2010; 2(2): 100-101.
- Jianming O, Xiugiona Y, Zexuan S, Fuzhai C. Simulation of calcium oxalate stone in vitro. Science in China Series B-Chemistry. 2003; 21. 46(3): 234-242 Qiu SR, Wierzbicki A, Orme CA, Cody AM, Hoyer JR, Nancollas GH,
- 22. Zepeda S, De Yorea SS -: Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc. Natl. Acad. Sci 2004; 19: 1811-1815.
- Badami S, Gupta MK, Ramaswamy S, Rai SR, Nanjaian M, Bendell DJ, Subban R, Bhojaraj S.: Determination of betulin in *Grewia* 23.
- titiaefolia by HPTLC. Separation Sci. 2004; 27: 129-131. Vidya L, Varalakshmi P.: Control of urinary risk factors of stones 24. by betulin and. Lupeol in experimental hyperoxaluria. Fitoterapia, 2000; 75: 533-543
- Badami S, Vijayan R, Mathew N, Chandrashekhar R, Godavarthi A, Dhanaraj SA, Suresh B.: In vitro cytotoxic properties of Grew titiaefolia bark and lupeol. Indian J. Pharmacol. 2003; 35: 250-251.
- 6. <u>Khan NI, Shinge IS, Naikwade NS, Antilithiatic effect of</u> *Helianthus annuus* Linn. Leaf extract in ethylene glycol and ammonium chloride induced nephrolithiasis. Int. J. Pharmacy Pharma, Sci. 2010: 2: 180-184.

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt. Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic

Formatted: Font: Cambria, 8 pt, Not Italic

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

Formatted: Font: Cambria, 8 pt, Not Italic

Formatted: Font: Cambria, 8 pt, Not Italic, Font color: Auto

# Int J Pharm Pharm Sci, Vol 4, Suppl 1,261-270